Amarin (NASDAQ:AMRN) Releases Quarterly Earnings Results, Beats Expectations By $0.11 EPS

Amarin (NASDAQ:AMRN) announced its earnings results on Wednesday. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.11, Zacks reports. The firm had revenue of $39.55 million during the quarter, compared to analyst estimates of $43.76 million.

Here are the key takeaways from Amarin’s conference call:

• Positive Sentiment: Amarin reported its first profitable quarter in two years, with Q3 net income of $245,000 versus a $7.7 million loss a year earlier, $9 million in positive operating cash flow, and $324 million in cash and investments with no debt.
• Positive Sentiment: International momentum remained strong: European VAZKEPA in-market demand rose an estimated 68% year over year, total global partner demand increased 55%, and launches in Poland, Singapore, and South Korea are expanding the commercial opportunity.
• Negative Sentiment: Q3 revenue fell to $39.6 million from $49.7 million, primarily because U.S. pricing pressure and generic competition reduced net selling prices despite stable branded prescription volume; management expects pricing pressure to continue into 2027.
• Positive Sentiment: Amarin maintained a 47% share of the U.S. IPE market, reduced operating expenses by 44% year over year, improved gross margins sequentially through renegotiated supply contracts, and expects positive operating cash flow for the full year.
• Neutral Sentiment: The investigator-led EMT-2 colorectal cancer trial did not meet its primary progression-free-survival endpoint but showed a statistically significant 32% reduction in the hazard of death on overall survival; Amarin is evaluating the data and potential commercial and development paths, including possible partnerships.

Amarin Stock Performance

Shares of AMRN traded up $0.77 during mid-day trading on Wednesday, reaching $12.72. 64,357 shares of the company’s stock traded hands, compared to its average volume of 74,982. Amarin has a 12 month low of $11.25 and a 12 month high of $18.50. The stock has a market capitalization of $268.73 million, a P/E ratio of -12.86 and a beta of 0.76. The business’s 50-day moving average price is $13.07 and its 200-day moving average price is $14.37.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on AMRN shares. JPMorgan Chase & Co. assumed coverage on shares of Amarin in a research report on Friday, August 21st. They set an “underweight” rating and a $13.00 price target for the company. Zacks Research upgraded Amarin from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amarin in a report on Thursday, October 15th. Finally, Wall Street Zen downgraded shares of Amarin from a “buy” rating to a “hold” rating in a research report on Saturday, July 25th. One investment analyst has rated the stock with a Strong Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $13.00.

Amarin Company Profile

Amarin Corporation plc is a biopharmaceutical company focused on developing and commercializing therapies intended to reduce cardiovascular risk. Its principal product is VASCEPA (icosapent ethyl), a prescription omega-3 fatty-acid medicine derived from highly purified eicosapentaenoic acid.

VASCEPA was initially approved in the United States to help lower triglyceride levels in certain patients and later received expanded approval to reduce the risk of cardiovascular events in eligible adults with elevated cardiovascular risk.